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Abstract 
 
Staphylococcus aureus responsible for nosocomial infections is a significant threat to the 
public health. The increasing resistance of S. aureus to various antibiotics has drawn it to 
a prime focus for research on designing an appropriate drug delivery system. Emergence 
of Methicillin Resistant Staphylococcus aureus (MRSA) in 1961, necessitated the use of 
vancomycin “the drug of last resort” to treat these infections(6). Unfortunately, S. aureus 
has already started gaining resistances to vancomycin(5). Liposome encapsulation of 
drugs have been earlier shown to provide an efficient method of microbial inhibition in 
many cases(9). We have studied the effect of liposome encapsulated vancomycin on 
MRSA and evaluated the antibacterial activity of the liposome-entrapped drug in 
comparison to that of the free drug based on the minimum inhibitory concentration (MIC) 
of the drug. The MIC for liposomal vancomycin was found to be about half of that of free 
vancomycin. The growth response of MRSA showed that the liposomal vancomycin 
induced the culture to go into bacteriostatic state and phagocytic killing was enhanced. 
Administration of the antibiotic encapsulated in liposome thus was shown to greatly 
improve the drug delivery as well as the drug resistance caused by MRSA. 
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Introduction 
 
Staphylococcal infections often occur exclusively in hospitals, playing on 
vulnerable patients, such as those with compromised immune systems or who had just 
undergone surgery. Earlier the introduction of penicillin in the 1940s stemmed staph 
infections in hospitals. However, staph strains quickly developed resistance to 
penicillin(23). Subsequently, methicillin, synthetic penicillin was developed but 
Staphylococcus quickly learned to evade it, as well. Methicillin resistant Staphylococcus 
aureus (MRSA) is now resistant to an entire class of penicillin-like antibiotics called 
beta-lactams. In 2002, physicians in the United States documented the first S. aureus 
strains resistant to the antibiotic, vancomycin, which had been one of the handful of 
antibiotics of last resort for use against S. aureus. Though it is feared that this could 
quickly become a major issue in antibiotic resistance, so far vancomycin- resistant strains 
are still rare(6, 23). 
 
Vancomycin blocks the important substrates for cell wall synthesizing machinery, 
i.e. the D-alanyl-D-alanine residue (DDR) of the lipid II precursor in the cytoplasmic 
membrane of the bacterial cell(23). Thereby, it inhibits utilization of the substrates by 
glycosyltransferase (a cell wall synthesis enzyme) to produce the nascent peptidoglycan 
chain. However, besides the lipid II murein monomer precursors, which are the real 
targets of vancomycin, the cell wall peptidoglycan of a single S. aureus cell is known to 
posses about 6.0 x 10
6
 DDRs to which vancomycin molecules could bind while 
penetrating the peptidoglycan layers and therefore is an inefficient drug in terms of 
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maintaining an efficacious concentration around its real targets. Mechanistically the 
thickened cell wall is thought to limit the access of vancomycin to its target in MRSA 
strains(5). 
 
Drug delivery is a major issue and delivery of free drug is often inefficient 
because the large size and low solubility of the drug in biofluid, lower penetration ability 
into the pathogens, development of drug resistance by the pathogen and other side 
effects(18). Encapsulation of the drug into liposomal vesicles can stabilize the drug and 
help in efficient delivery(14). The interaction of dioleoylphosphatidylcholine vesicles 
with murine tumor cells reported recently, which showed that small amounts of solute 
could be transferred from vesicles into cells(3). As shown by fluorescence microscopy 
and by fluorescence photobleaching recovery measurements, most of the vesicles were 
stably adsorbed on the cell surface with little incorporation of vesicle lipid into the cell 
membrane(3, 14). Liposomal encapsulation of tuberculostatic drugs such as isoniazid, 
pyrazinamide, rifampicin etc., in distearoyl phosphatidylcholine/cholesterol liposomes 
were shown to increase their therapeutic index(12). Soybean phospholipid 
(phosphatidylcholine) is a natural product, non toxic, biodegradable and non allergic(16) 
lipid. Liposome made up of Soybean phospholipid would be of advantage in drug 
delivery. The chances of drug resistance increases on the use of free drug since the 
pathogens are more likely to acquire resistance when exposed continuously to the drugs. 
Liposomes encapsulate the drug and thus prevent its exposure to the organism. They also 
reduce the time of exposure of the drug to the cell surface of the pathogen and hence do 
not allow the pathogens the time to develop resistance mechanisms. The liposome 
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encapsulated drug thus may make the pathogens susceptible to low concentration of the 
drug(9, 11).   
 
Liposomal drug delivery systems can contribute (i) to targeting of the drug to the 
infected tissues, (ii) in increasing intracellular antibiotic concentrations, and (iii) in 
reducing toxicity of potentially toxic drugs in certain cases(9, 17). As with most of the 
drug carriers, liposomes have been extensively used in an attempt to improve the 
selective delivery of antimicrobial agents and to reduce the side effects of the drug to 
some extent(6, 8, 11, 18). Encapsulation of ampicillin (Amp) in liposomes prepared with 
synthetic lecithins was shown to enhance its antibiotic activity against both Amp-
sensitive and Amp-resistant Escherichia coli(22). Since the drug is encapsulated inside 
the vesicle, the recognition of the vesicle by the infected site is important for the targeting 
and the drug itself would have much less interaction with biofluid and associated 
components. This could reduce drug resistance caused due to delivery of free drug  into 
the system to some extent(2).  
 
To test this hypothesis in an in vitro set up, the culture of Methicillin Resistant 
Staphylococcus aureus (MRSA) was treated with the liposomal vancomycin preparation. 
This liposomal vancomycin preparation was then tested on the MRSA culture in 
comparison to free vancomycin to determine the minimum inhibitory concentrations(11, 
18) of both the forms of the drug. The growth response of MRSA on exposure to the free 
drug and the liposomal drug delivery systems were monitored using growth curves over a 
period of six hours. The effect of liposomal vancomycin on phagocytosis was also 
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studied. Lastly, the efficacy of the liposomal vancomycin on storage of the liposomal 
preparation was checked for a period of three months. 
 
 
Materials and Methods 
 
Characterization of  Methicillin resistant Staphylococcus aureus :  For all inoculation 
purposes the culture density was adjusted to 0.1 OD at 530 nm in Muller-Hinton Broth 
(MHB) containing 2% NaCl(9, 20). Antibiotic susceptibility test – Kirby Bauer method 
to reconfirm that the procured Staphylococcus aureus culture was Vancomycin 
intermediate was carried out using Muller-Hinton Agar containing 2% NaCl. The 
antibiotic disc used was vancomycin (10 µg) disc. Well isolated colony of MRSA was 
added to 3mL of MH- broth incubated at 37
0
C for 3 hours density adjusted to 0.5 OD at 
530 nm. The plates were incubated at 37
0
C for 24 hours. Bioassay using vancomycin 
drug VANSAFE- CP by VBH Medisciences Ltd. used in the experiment was carried out 
to indicate that the test organism is likely to respond to therapy.  
 
Preparation of liposome: Soybean phospholipid was prepared by using reported 
method(9, 19). The purified Soybean phospholipid was dissolved in 1ml of chloroform 
and then subjected to nitrogen gas to evaporate the chloroform from the vial. A thin layer 
of phospholipid is formed on the inside wall of the vial. This was then vacuum dried at 
37
0
C
 
/ 3 hrs. Rehydration was carried out by adding 1ml of distilled water for plain 
liposome. In case of drug loaded liposome: 50mg/ml of vancomycin dissolved in distilled 
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water was added to the vacuum dried vial. This was then subjected to 10 cycles of freeze 
and thaw (liquid nitrogen – 400 C water bath). To obtain small unilamellar vesicles, the 
solution was passed through a stainless steel extrusion device (Unimetrics, Illinois, USA), 
first with a 0.2 µm membrane (Costar Scientific, MA) and then with a 0.05 µm 
membrane. A PerkinElmer UV-Vis-NIR spectrometer was used for absorption spectra of 
vancomycin and vancomycin entrapped liposomes to determine the concentration of 
vancomycin in the samples. The hydrodynamic radius was determined using Dynamic 
light scattering (DynaPro 99).  
 
Susceptibility test procedure: The antimicrobial activity of vancomycin –loaded 
liposomes was determined in comparison with that of the free drug, with Minimum 
inhibitory concentration using the standard broth microdilution assay(7, 9, 21). Minimum 
inhibitory concentration (MIC), is the lowest concentration of an antimicrobial agent that 
will inhibit the visible growth of a microorganism after overnight incubation. Stock 
solutions of liposomal vancomycin (117µg/ml) and free vancomycin (50 µg/ml) were 
used. Appropriate controls were maintained. Plates were incubated at 37°C for 24 hours. 
Each assay was repeated three times. 
 
Growth response: growth curve was carried out to check the effect of subleathal- MIC 
concentrations of  liposomal vancomycin and free vancomycin in comparison to normal 
curve (in absence of any form of drug). 100µl of culture (0.1 OD) was added to 4.9ml of 
Muller-Hinton Broth (MHB). A control i.e. without the drug was used. Total volume was 
10ml. Readings were taken at intervals of 30 minutes for 6 hours.  
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Phagocytosis: Phagocytosis in presences of liposomal vancomycin was studied using 
phagocytosis experiment(15). To separate leukocyte from the whole blood, 1.5 mL of 3% 
dextran in saline is added to 5mL of heparinised blood. Then leukocyte rich plasma is 
separated from red blood cells by centrifuging it at 100 rpm/ 10min. For phagocytosis 
assay three tubes are used labeled as Control, Test 1and Test2. In each tube 0.25 ml AB 
serum, 0.25 mL Hanks balanced salt solution, 0.25 mL S. aureus and 0.25 mL Leukocyte 
(except in control) is added and incubated at 37
0
C/1hr. In Test2 after a 30 min/37
0
C 
0.25mL liposomal vancomycin is added. After incubation period 1mL cold Trypan blue 
dye is added to each tube. Centrifuged at 1500 rpm/ 10min. supernatant is discarded and 
the cells suspended in the remaining volume, mixed thoroughly. Examined using a 
hemocytometer, dead cells blue and live cells yellow using light microscope. 
 
Efficiency of liposomal drug on storage: The effect of material of storage namely 
plastic and glass and effect of temperature (4
0
C)(2) on the antibacterial efficiency of the 
vancomycin loaded liposome (liposomal drug) was carried out by storing the colloidal 
suspension in plastic and glass vials under Refrigeration (4
0
C) for a period of 3 months. 
At interval of one month the efficiency testing was carried out by determining the MIC- 
using micro-broth dilution method(7, 9) (method mentioned above). 
 
 
Results & Discussion  
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Characterization of Methicillin Resistant Staphylococcus aureus: The antibiotic 
susceptibility assay was carried out using Kirby Bauer method(21) to reconfirm its 
sensitivity  to vancomycin. These zone size of 20mm for vancomycin disc agreed with 
that expected for S. aureus ATCC 25923 (17-22mm) as reported earlier. The bioassay 
results indicated that the MRSA culture showed „intermediate susceptibility‟ to the 
vancomycin drug VANSAFE-CP which was planed to be used as the drug for the  
experiment, indicating that the test organism is likely to respond to therapy with this 
drug. 
 
Determination of concentration of vancomycin entrapped liposome: The UV-visible 
absorption spectra of vancomycin shows characteristic peak at 280nm (Figure 1). The 
extinction coefficient of the drug at 280nm was determined to be 8743/mol/cm. The plain 
liposome prepared from soybean phospholipid did not show any appreciable absorbance 
at 280nm but the absorption spectra of the drug encapsulated liposome showed the 
absorption band at 280 nm which can only be due to the presence of vancomycin. The 
concentration of vancomycin entrapped in the liposome was found to be 11730µg/mL as 
determined from the UV-visible absorption spectra.  
 
Characterization of liposome: Hydrodynamic radius of plain liposomes and liposomal 
vancomycin was determined using dynamic light scattering (DLS) technique. Since the 
liposomes are present in a colloidal suspension they are in continuous Brownian motion. 
To determine the hydrodynamic radius of the liposomes, a monomodal distribution of 
size was considered in the analyses of the DLS data. The hydrodynamic radius for plain 
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liposome and vancomycin loaded liposome were found to be 123 nm and 157 nm 
respectively (figure 2). The size distribution of the liposomes observed in the present case 
agree well with earlier reports(13). 
 
Susceptibility test procedure: Minimum inhibitory concentration (MIC) of liposomal 
vancomycin as compared to free vancomycin was determined using micro broth dilution 
method(7, 9, 21). Standard vancomycin powder is expected to give MIC values in the 
range of 0.5µg/mL to 2.0µg/mL (NCCLS)(1, 7). The assay of the inhibitory effect based 
on the determination of turbidity as a signature of presences of growth showed that the 
MIC of free vancomycin for MRSA in our preparation was 1.5 -1.6µg/mL, which is in 
the range given in the NCCLS chart. 
 
Controls with plain liposomes were maintained and it was observed that the plain 
liposomes did not show any inhibitory effect on MRSA growth. Thus ensuring that the 
inhibitory effect if any observed was solely due to the drug and the delivery system. The 
assay showed for vancomycin entrapped liposomes was 0.8µg/mL (figure 3). Thus the 
MIC for vancomycin decreased to half when the drug was delivered using liposomal 
encapsulation. In other words, using liposomal drug delivery system the concentration of 
vancomycin required to inhibit the same volume of culture was half the concentration 
required when the same vancomycin is delivered in the free form. 
 
Thus strongly indicating that liposomal drug delivery system is a very effective 
system for drug delivery(14, 21). Since low concentration of drug is required to inhibit 
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the culture the chances of resistance induced due to exposure to high concentration of 
drug can be combated. 
 
Growth curve analysis: To check the effect of liposomal drug in comparison with the 
free drug on the growth cycle of MRSA growth curve studies were carried out. Half the 
MIC i.e. sub-lethal concentration of the free vancomycin and liposomal vancomycin was 
used to study growth curve response. The growth curve of MRSA showed exponential 
growth with time under normal conditions of growth i.e. in the absence of any form of 
drug (neither free vancomycin nor liposomal vancomycin) the culture showed a short lag 
phase and soon entered the log phase of growth within one hour  (figure 4). With free 
vancomycin the culture showed a longer lag phase and entered the log phase only after 
two hours and with time the curve showed a plateau indicating arrest of cell 
multiplication. This indicated that the free vancomycin has considerable inhibitory effect 
on MRSA. When the MRSA was exposed to liposomal vancomycin the culture showed 
no growth for three hours and negligible growth after six hours. This indicated that the 
cell growth was arrested as soon as the cells were exposed to liposomal vancomycin.  
 
Phagocytosis:  Phagocytosis in presences of liposomal vancomycin was studied using 
phagocytosis assay. The phagocytosis assay showed that in the presence of the drug-
loaded-liposome only dead (blue) cells were present in the phagocyte whereas in the 
control both the live (yellow) and the dead (blue) cells were present. This indicated that 
the drug was delivered efficiently into the phagocyte killing all the S. aureus cells 
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enhancing the bactericidal activity of the phagosome. This confirms that the liposomes 
increase the efficiency of drug delivery. 
 
Effect of storage on liposome: The effect of storage on liposomal vancomycin was 
studied with respect to time, temperature and material of storage. The MIC value 
remained consistent for a period of 3 months at refrigeration temperature (4
0
C)(2). When 
efficacy was tested on storage in plastic and glass vials no change in MIC values was 
observed for vancomycin entrapped liposomes i.e. the MIC value remained consistent for 
a period of 3 months. Thus indicating that the liposomal suspension can be stored 
efficiently at 4
0
C in a refrigerator, in either plastic or glass vials without the fear of losing 
its antibacterial activity at least for a period of 3 months.  
 
 
Conclusion 
 
The liposomal vancomycin was extremely effective in inhibiting the MRSA 
culture at lower concentration of vancomycin. The MIC values decreased from 1.6µg/mL 
to 0.8µg/mL when the drug in entrapped into soybean phospholipid. Thus indicating that 
the drug concentration required to inhibit the same volume culture reduced to half its 
concentration when delivered  using liposomes. The growth curve studies indicated that 
when MRSA is exposed to liposomal vancomycin it immediately enters into a static state 
with negligible growth over a period of six hours. Whereas, when exposed to free drug 
the culture enters into the log phase within two hours and multiplies steadily for the next 
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three hours after which the curve starts to plateau indicating that the culture has stoped 
multiplying. Thus the culture is inhibited at a faster rate when the the drug is entrapped in 
liposomes as compared to free drug.  Phagocytosed cells can be killed more efficiently 
and faster using liposomal vancomycin. 
 
Liposomal drug delivery system is more effective in inhibiting and eventually 
killing bacteria than the traditional free drug delivery system. The drug is delivered more 
efficiently using liposome at lower concentrations and at a faster rate i.e. short time 
interval to reach its target site in a concentrated form. Whereas when free drug is 
delivered the drug gets diluted by the time it reaches its real target i.e. longer time period 
are required with higher concentration of drug to inhibit the same volume of culture. By 
the time (longer time) the free drug reaches its real targets the drug is lost at various 
stages – cell wall, the drug is affected by enzymes in the cytoplasm (enzymatic action) 
hence (diluting) reducing the final effective concentration of the drug delivered. 
Liposomal drug delivery system seems to be the best option to cure infections and 
overcome drug resistant. 
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Figure Captions: 
 
 
[1]  UV-visible absorption spectra for vancomycin entrapped in liposomes 
(Lipo+Vanco: solid lines), free vancomycin (Free Vanc: dashed lines) and plain 
liposomes (Only Lipo: dotted lines).  
 
[2]  Dynamic light scattering of (A) Soybean liposome and (B) Liposome entrapped 
vancomycin. The results were analysed by mono-modal distribution to obtain the 
mean radius of the vescicles. 
 
[3]  Plot of minimum inhibitory concentration (MIC) of vancomycin for S. aureus 
with free vancomycin (empty squares), liposome entrapped vancomycin (solid 
triangles). Solid line represent positive control of the culture and dotted line is 
negative control (media without S. aureus).  
 
[4] Growth curves of S. aureus in presence of free vancomycin (solid circles), 
liposome entrapped vancomycin (solid triangles) and control i.e., without 
vancomycin/liposome (solid squares) 
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Figure 1: UV-visible absorption spectra for vancomycin entrapped in 
liposomes (Lipo+Vanco: solid lines), free vancomycin (Free Vanc: dashed 
lines) and plain liposomes (Only Lipo: dotted lines).  
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Figure 2: Dynamic light scattering of (A) Soybean liposome and 
(B) Liposome entrapped vancomycin. The results were analysed 
by mono-modal distribution to obtain the mean radius of the 
vescicles. 
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Figure 3: Plot of minimum inhibitory concentration (MIC) of vancomycin for S. aureus 
with free vancomycin (empty squares), liposome entrapped vancomycin (solid triangles). 
Solid line represent positive control of the culture and dotted line is negative control 
(media without S. aureus).  
 
 
 
 
 
Figure 4: Growth curves of S. aureus in presence of free vancomycin 
(solid circles), liposome entrapped vancomycin (solid triangles) and 
control i.e., without vancomycin/liposome (solid squares) 
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